Anti-Contactin-associated protein-like 2 antibodies (IgM)

Optimal result: 0 – 10 Units

Anti-Contactin-associated protein-like 2 (CASPR2) antibodies of the IgM class are less commonly reported compared to their IgG counterparts but represent an important aspect of the immune response in certain autoimmune neurological disorders. CASPR2 is a cell adhesion molecule that plays a significant role in the proper functioning of the nervous system, particularly in the juxtaparanodal regions of myelinated axons, where it helps to cluster potassium channels. These potassium channels are crucial for maintaining the electrical excitability of nerve cells. When anti-CASPR2 IgM antibodies target this protein, they can disrupt normal neuronal function, leading to a range of clinical manifestations.

Anti-Contactin-associated protein-like 2 (CASPR2) antibodies of the IgM class are less commonly reported compared to their IgG counterparts but represent an important aspect of the immune response in certain autoimmune neurological disorders. CASPR2 is a cell adhesion molecule that plays a significant role in the proper functioning of the nervous system, particularly in the juxtaparanodal regions of myelinated axons, where it helps to cluster potassium channels. These potassium channels are crucial for maintaining the electrical excitability of nerve cells. When anti-CASPR2 IgM antibodies target this protein, they can disrupt normal neuronal function, leading to a range of clinical manifestations.

The presence of IgM antibodies is generally indicative of an acute or recent onset of the immune response. In the context of anti-CASPR2 antibodies, IgM positivity can suggest a newly developed autoimmune reaction, potentially leading to neurological conditions such as limbic encephalitis, characterized by inflammation of the limbic system, or neuromyotonia, which involves muscle stiffness and spasms. Other associated conditions can include Morvan's syndrome, where patients experience a combination of neuromyotonia, autonomic dysfunction, and encephalitic symptoms.

Patients with anti-CASPR2 IgM antibodies might present with a variety of symptoms such as seizures, memory issues, sleep disturbances, and autonomic dysfunction, depending on the extent and location of the immune-mediated attack. These clinical features necessitate a comprehensive evaluation to rule out other potential causes and to confirm the autoimmune etiology.

The therapeutic approach to conditions associated with anti-CASPR2 IgM antibodies typically involves immunomodulatory treatments aimed at reducing the antibody-mediated immune response. This may include therapies such as corticosteroids, plasma exchange, or intravenous immunoglobulin (IVIG). In some cases, the detection of anti-CASPR2 IgM antibodies can also prompt a search for an underlying malignancy, as paraneoplastic syndromes can sometimes be associated with the presence of these antibodies.

While the detection of IgM class antibodies against CASPR2 is less common and less studied than IgG, their presence is still a crucial diagnostic clue and can have significant implications for the management and prognosis of affected individuals. Ongoing research into the role of IgM antibodies in autoimmune neurological disorders continues to shed light on their pathogenic potential and the mechanisms through which they contribute to disease processes.

Anti-Contactin-associated protein-like 2 antibodies (IgM)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Anti-Contactin-associated protein-like 2 antibodies (IgM) — 10,000+ markers explained
One Anti-Contactin-associated protein-like 2 antibodies (IgM) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro